Abstract:Statins, the lipid-lowering drugs, and non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH), a lipid-related pathology, share a complex relationship, one known to be hepatotoxic and other being hepatic injury. NASH is an unresolved mystery in terms of treatment. Could statins prove to be a promising solution due to their pleiotropic properties in addition to the cholesterol-lowering effect? This study aims to find statin effectiveness in NAFLD/NASH treatment and prevention of associated adverse outcomes. An extensive data search was done to identify the studies assessing statin effect on NAFLD/NASH and then analyzed to establish the relationship. Several studies demonstrated a reduction in NAFLD/NASH-associated inflammation and fibrosis with statin treatment. These anti-inflammatory and anti-fibrotic effects were through their pleiotropic properties, which were in addition to their cholesterol-lowering effect. In various animal studies, statins were found to improve hepatic lipotoxicity, oxidative stress, inflammatory responses, and fibrosis associated with NASH through multiple pathways. Statins exert these protective effects by recovering the gene expression level of peroxisomal proliferator-activated receptor alpha (PPARα) and therefore restore the mitochondrial and peroxisomal fatty acid oxidation (FAO). Statin treatment also increased the levels of paraoxonase 1 (PON1), an antioxidant and antiatherogenic enzyme that is reduced in NAFLD as well as encounter the hepatic lipotoxicity by resolving cholesterol crystals and Kupffer cells (KCs) with crown-like structures (CLSs). They exhibited antitumor properties by inhibiting proinflammatory cytokines and vascular proliferative factors. Moreover, they restored a healthy liver sinusoidal endothelial cell (LSEC) and hepatic stellate cells (HSC) along with inhibiting the activation of HSC via modulating inducible nitric oxide synthase (iNOS) and expressions of endothelial nitric oxide synthase (eNOS). Besides, they were protective against cardiovascular disease (CVD)-related morbidity and mortality, hepatocellular carcinoma (HCC), and metabolic syndrome (MS) associated with NAFLD/NASH. NASH and its precursor, NAFLD, could be treated and prevented with statins owing to their pleiotropic properties. This study helps to prove this by looking back at different literature and has successfully enlightened the point. Once proved through large clinical trials on humans, it could revolutionize the NASH therapy.

Impact of statin therapy on CD40:CD40L signaling: mechanistic insights and therapeutic opportunities

Anti-inflammatory Action of Statins in Cardiovascular Disease: the Role of Inflammasome and Toll-Like Receptor Pathways

Dual Effects of Statins Therapy in Systemic Lupus Erythematosus and SLE-related Atherosclerosis: the Potential Role for Regulatory T Cells

Regulatory impact of statins on macrophage polarization: mechanistic and therapeutic implications

To cardiovascular disease and beyond: new therapeutic perspectives of statins in autoimmune diseases and cancer

Overview of Therapeutic Effects of Statins on Inflammatory Diseases Through Regulating Adhesive Molecules

Antioxidant Effects of Statins by Modulating Nrf2 and Nrf2/HO-1 Signaling in Different Diseases

Targeting AMPK by Statins: A Potential Therapeutic Approach

Dissecting the multifaceted impact of statin use on fatty liver disease: a multidimensional study

A review of high-dose statin therapy: targeting cholesterol and inflammation in atherosclerosis

Statins in Chronic Liver Disease: Review of the Literature and Future Role

Statins: Epidrugs with Effects on Endothelial Health?

Effect of Statins on Platelet Activation and Function: From Molecular Pathways to Clinical Effects

Regulatory effects and potential mechanisms of statins on immune cells

Overview of therapeutic effects of stains on inflammatory diseases through regulating adhesive molecules.

Simvastatin Inhibits IL-17 Secretion by Targeting Multiple IL-17-Regulatory Cytokines and by Inhibiting the Expression of IL-17 Transcription Factor RORC in CD4+ Lymphocytes

Pleiotropic Effects of Statins in the Light of Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis

Statins Induce the Accumulation of Regulatory T Cells in Atherosclerotic Plaque

Statins Promote Interleukin-1β–Dependent Adipocyte Insulin Resistance Through Lower Prenylation, Not Cholesterol

Impact of Simvastatin on Adipose Tissue: Pleiotropic Effects in Vivo

Co-stimulators CD40-CD40L, a potential immune-therapy target for atherosclerosis: A review